STOCK TITAN

IRIDEX (IRIX) CFO increases direct holdings to 100,440 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IRIDEX CORP Chief Financial Officer Romeo R. Dizon reported open-market purchases of the company’s common stock. On January 20, 2026, he bought 2,100 shares at a price of $1.4987 per share. On January 21, 2026, he made two additional purchases of 409 shares at $1.53 per share and 1,750 shares at $1.49 per share.

After these transactions, Dizon directly owned 100,440 shares of IRIDEX common stock. The filing indicates these holdings are reported as directly owned, with no indirect ownership relationships noted.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/20/2026 P 2,100 A $1.4987 98,281 D
Common Stock 01/21/2026 P 409 A $1.53 98,690 D
Common Stock 01/21/2026 P 1,750 A $1.49 100,440 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 01/21/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRIDEX (IRIX) report for its CFO?

The Chief Financial Officer, Romeo R. Dizon, reported open-market purchases of IRIDEX common stock on January 20 and January 21, 2026.

How many IRIDEX (IRIX) shares did the CFO buy on January 20, 2026?

On January 20, 2026, the CFO purchased 2,100 shares of IRIDEX common stock at a price of $1.4987 per share.

What IRIDEX (IRIX) insider trades occurred on January 21, 2026?

On January 21, 2026, the CFO bought 409 shares at $1.53 per share and 1,750 shares at $1.49 per share of IRIDEX common stock.

What is the CFO’s total direct IRIDEX (IRIX) share ownership after these trades?

Following the reported transactions, the CFO directly owned 100,440 shares of IRIDEX common stock.

Are the reported IRIDEX (IRIX) shares held directly or indirectly by the CFO?

The filing shows the CFO’s 100,440 shares as held with direct ownership, with no nature of indirect beneficial ownership indicated.

Does the IRIDEX (IRIX) Form 4 mention any derivative securities for the CFO?

The Form 4 includes a table for derivative securities, but no derivative transactions are reported for the CFO in this filing.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

26.82M
11.96M
27.64%
15.83%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW